Diona Simoneit - 01 Apr 2022 Form 3 Insider Report for Oncology Institute, Inc. (TOI)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
3
Accepted by SEC
05 Apr 2022, 17:44:07 UTC
Next SEC filing
22 Nov 2022
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Mark Hueppelsheuser, Attorney-in-Fact for Diona Simoneit

Key filing fact

Diona Simoneit filed Form 3 for Oncology Institute, Inc. (TOI) on 05 Apr 2022.

Key facts

  • This page summarizes Diona Simoneit's Form 3 filing for Oncology Institute, Inc. (TOI).
  • 0 reported transactions and 4 derivative rows are listed below.
  • Accepted by SEC: 05 Apr 2022, 17:44.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TOI holding

Earnout Shares 1 (Common Stock)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
7,454
Date
01 Apr 2022
Ownership
Direct
Footnotes
F1
TOI holding

Earnout Shares 2 (Common Stock)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
11,182
Date
01 Apr 2022
Ownership
Direct
Footnotes
F2
TOI holding

Common stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
2,058
Date
01 Apr 2022
Ownership
Direct
Footnotes
F3
TOI holding

Common stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
8,814
Date
01 Apr 2022
Ownership
Direct
Footnotes
F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TOI holding Derivative

Stock Options (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Apr 2022
Ownership
Direct
Underlying class
Common stock
Underlying amount
81,814
Exercise price
$0.8600
Footnotes
F5
TOI holding Derivative

Stock Options (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Apr 2022
Ownership
Direct
Underlying class
Common stock
Underlying amount
14,080
Exercise price
$0.8600
Footnotes
F6
TOI holding Derivative

Stock Options (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Apr 2022
Ownership
Direct
Underlying class
Common stock
Underlying amount
10,488
Exercise price
$7.09
Footnotes
F7
TOI holding Derivative

Stock Options (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
01 Apr 2022
Ownership
Direct
Underlying class
Common stock
Underlying amount
44,741
Exercise price
$7.09
Footnotes
F8
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 8 footnotes

Footnote F1

Represents restricted earn-out shares subject to forfeiture and unvested until such time that the Issuer's stock price reaches $12.50 per share for 20 days within any 30 consecutive trading days for the two-year period following the closing of the business combination of the Issuer, pursuant to that certain Agreement and Plan of Merger dated as of June 28, 2021, by and among DFP Healthcare Acquisitions Corp., Orion Merger Sub I, Inc., Orion Merger Sub II, LLC, and TOI Parent, Inc., that closed on November 12, 2021 (the "Business Combination"), subject to continued employment at such time.

Footnote F2

Represents restricted earn-out shares subject to forfeiture and unvested until such time that the Issuer's stock price reaches $15.00 per share for 20 days within any 30 consecutive trading days for the three-year period following the closing of the Business Combination, subject to continued employment at such time.

Footnote F3

Represents restricted stock units ("RSUs") that vest in four equal annual installments on each of the first four anniversaries of November 12, 2021 (the "Vesting Commencement Date"), with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates.

Footnote F4

Represents RSUs with 1/3rd of the RSUs vesting on the second anniversary of the Vesting Commencement Date, with the remaining RSUs vesting in four equal annual installments beginning on the third anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the sixth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates.

Footnote F5

These options vest as to 1/4th of the total number of shares subject to the option on the first anniversary of January 11, 2021 (the "Original Grant Date"), and as to 1/36th of the total number of shares monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Original Grant Date, subject to continued employment through the vest date.

Footnote F6

These options vest monthly for 36 months following November 12, 2021, the date of the closing of the Business Combination, subject to continued employment through the vest date.

Footnote F7

The stock options vest in four equal annual installments on each of the first four anniversaries of the Vesting Commencement Date, with all options becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates.

Footnote F8

The stock options vest as to 1/3rd of the options granted on the second anniversary of the Vesting Commencement Date, with the remaining options vesting in four equal annual installments beginning on the third anniversary of the Vesting Commencement Date, with all options becoming vested on the sixth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .